Journal of Stroke & Cerebrovascular Diseases
Volume 12, Issue 1 , Pages 17-21 , January 2003

Effect of edaravone on cerebral vasospasm following experimental subarachnoid hemorrhage

  • Tadayoshi Nakagomi, MD

      Affiliations

    • Department of Neurosurgery, Teikyo University School of Medicine, Tokyo, Japan
    • ,
  • Kenta Yamakawa, MD

      Affiliations

    • Yamakawa Neurological Clinic, Tokyo, Japan
    • ,
  • Tomio Sasaki, MD

      Affiliations

    • Department of Neurosurgery, Neurological Institute, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
    • ,
  • Isamu Saito, MD

      Affiliations

    • Department of Neurosurgery, Kyorin University School of Medicine, Tokyo, Japan
    • ,
  • Kintomo Takakura, MD

      Affiliations

    • Department of Neurosurgery, Neurological Institute, Tokyo Women's Medical University, Tokyo, Japan

Received 2 August 2002 ,Revised 15 October 2002 ,Accepted 19 October 2002.

References 

  1. Dorsch NWC, King MT. A review of cerebral vasospasm in aneurysmal subarachnoid hemorrhage. J Clin Neurosci. 1994;1:19–26
  2. Gutteridge JMC. Iron promoters of the Fenton reaction and lipid peroxidation can be released from hemoglobin by peroxides. FEBS Lett. 1986;201:291–295
  3. Kellogg EW, Fridovich I. Liposome oxidation and erythrocyte lysis by enzymically generated superoxide and hydrogen peroxide. J Biol Chem. 1977;252:6721–6728
  4. Winterbourn CC, McGrath BM, Carrell RW. Reactions involving superoxide and normal and unstable haemoglobin. Biochem J. 1976;155:493–502
  5. Asano T, Sasaki T, Koide T, et al.  Experimental evaluation of the beneficial effect of an antioxidant on cerebral vasospasm. Neurol Res. 1984;6:49–53
  6. Asano T, Takakura K, Sano K, et al.  Effects of a hydroxy radical scavenger on delayed ischemic neurological deficits following aneurysmal subarachnoid hemorrhage: results of a multicenter, placebo-controlled double-blind trial. J Neurosurg. 1996;84:792–803
  7. Echlin F. Experimental vasospasm, acute and chronic, due to blood in the subarachnoid space. J Neurosurg. 1971;35:646–656
  8. Fisher CM, Kistler JP, Davis JM. Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery. 1980;6:1–9
  9. Macdonald RI, Weir BKA. A review of hemoglobin and the pathogenesis of cerebral vasospasm. Stroke. 1991;22:971–982
  10. Mayberg MR, Okada T, Bark DH. The role of hemoglobin in arterial narrowing after subarachnoid hemorrhage. J Neurosurg. 1990;72:634–640
  11. Saito I, Asano T, Sano K, et al.  Neuroprotective effect of an antioxidant, ebselen, in patients with delayed neurological deficits after aneurysmal subarachnoid hemorrhage. Neurosurgery. 1998;42:269–277
  12. Tanishima T. Cerebral vasospasm: contractile activity of hemoglobin in isolated canine basilar arteries. J Neurosurg. 1980;53:787–793
  13. Murota S, Morita I, Suda N. The control of vascular endothelial injury. Ann NY Acad Sci. 1990;598:182–187
  14. Watanabe T, Morita I, Nishi H, et al.  Preventive effect of MCI-186 on 15-HPETE induced vascular endothelial cell injury in vitro. Prostaglandins Leukot Essent Fatty Acids. 1988;33:81–87
  15. Watanabe T, Yuki S, Egawa M, et al.  Protective effects of MCI-186 on cerebral ischemia: Possible involvement of free radical scavenging and antioxidant actions. J Pharmacol Exp Ther. 1994;268:1597–1604
  16. Abe K, Yuki S, Kogure K. Strong attenuation of ischemic and postischemic brain edema in rats by a novel free radical scavenger. Stroke. 1988;19:480–485
  17. Kawai H, Nakai H, Suga M, et al.  Effects of a novel free radical scavenger, MCI-186, on ischemic brain damage in the rat distal middle cerebral artery occlusion model. J Pharmacol Exp Ther. 1997;281:921–927
  18. Mizuno A, Umemura K, Nakashima M. Inhibitory effect of MCI-186, a free radical scavenger, on cerebral ischemia following rat middle cerebral artery occlusion. Gen Pharmacol. 1998;30:575–578
  19. Kassell NF, Peerless SJ, Durward QJ, et al.  Treatment of ischemic deficits from vasospasm with intravascular volume expansion and induced arterial hypertension. Neurosurgery. 1982;11:337–343
  20. Origitano TC, Wascher TM, Reichman OH, et al.  Sustained increased cerebral blood flow with prophylactic hypertensive hypervolemic hemodilution (triple-H therapy) after subarachnoid hemorrhage. Neurosurgery. 1990;27:729–739
  21. Feigin VL, Rinkel GJE, Algra A, et al.  Calcium antagonists for aneurysmal subarachnoid hemorrhage. [Cochrane Review] Cochrane Database of Systemic Reviews. 2000;(2): Oxford: Update Software
  22. Flamm ES, Adams HP, Beck DW, et al.  Dose-escalation study of intravenous nicardipine in patients with aneurysmal subarachnoid hemorrhage. J Neurosurg. 1988;68:393–400
  23. Pickard JD, Murray GD, Illingworth R, et al.  Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid hemorrhage: British aneurysmal nimodipine trial. Br Med J. 1989;298:636–642
  24. Shibuya M, Suzuki Y, Sugita K, et al.  Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage: results of a prospective placebo-controlled double-blind trial. J Neurosurg. 1992;74:571–577
  25. Findley JM, Kassell NF, Weir BKA, et al.  A randomized trial of intraoperative, intracisternal tissue plasminogen activator for the prevention of vasospasm. Neurosurgery. 1995;37:168–178
  26. Kodama N, Sasaki T, Kawakami M, et al.  Cisternal irrigation therapy with urokinase and ascorbic acid for prevention of vasospasm after aneurysmal subarachnoid hemorrhage. Surg Neurol. 2000;53:110–118
  27. Mizoi K, Yoshimoto T, Takahashi M, et al.  Prospective study on the prevention of cerebral vasospasm by intrathecal fibrinolytic therapy with tissue type plasminogen activator. J Neurosurg. 1993;78:430–437
  28. Nakagomi T, Takagi K, Narita K, et al.  Cisternal washing therapy for the prevention of cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Acta Neurochir. 2001;77(suppl):161–165
  29. Ohman J, Servo A, Heiskanen O. Effect of intrathecal fibrinolytic therapy on clot lysis and vasospasm in patients with aneurysmal subarachnoid hemorrhage. J Neurosurg. 1991;75:197–201
  30. Sasaki T, Ohta T, Kikuchi H, et al.  A phase II clinical trial of recombinant human tissue-type plasminogen activator against cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Neurosurgery. 1994;35:597–605
  31. Zabranski JM, Spetzler RF, Lee HKS, et al.  Phase I trial of tissue plasminogen activator for the prevention of vasospasm in patients with subarachnoid hemorrhage. J Neurosurg. 1991;75:189–196
  32. Finn SS, Stephensen SA, Miller CA, et al.  Observations on the perioperative management of aneurysmal subarachnoid hemorrhage. J Neurosurg. 1986;65:48–62
  33. Zuccarello M, Marsch JT, Schmitt G, et al.  Effect of the 21-aminosteroid U-74006F on cerebral vasospasm following subarachnoid hemorrhage. J Neurosurg. 1989;71:98–104
  34. Watanabe T, Nishiyama M, Hori T, et al.  Ebselen (DR3305) ameliorates delayed cerebral vasospasm in a canine two-hemorrhage model. Neurol Res. 1997;19:563–565
  35. Kassell NF, Haley EC, Apperson-Hansen C, et al.  Randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in Europe, Australia, and New Zealand. J Neurosurg. 1996;84:221–228

☆ Address reprint requests to: Tadayoshi Nakagomi, MD, Department of Neurosurgery, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan.

PII: S1052-3057(02)45902-2

doi: 10.1053/jscd.2003.2

Journal of Stroke & Cerebrovascular Diseases
Volume 12, Issue 1 , Pages 17-21 , January 2003

Article Tools

* Image Usage & Resolution